BHVN — Biohaven Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1935979 ·
Last close
$13.24
Market Cap
$2.00B
52W High
$18.24
52W Low
$8.03
ADV30
3,184,993
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -126,420,000 | -129,279,000 | 263,676,000 | 95,754,000 | 361,923,000 |
| Jun 2026 | 0 | — | -124,899,000 | -137,311,000 | 370,739,000 | 238,033,000 | 358,517,000 |
| Mar 2026 | 0 | — | -130,428,000 | -130,532,000 | 466,406,000 | 273,074,000 | 336,906,000 |
| Dec 2025 | 0 | — | -142,734,000 | -145,555,000 | 451,447,000 | 229,957,000 | 399,375,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-511,395,000
Investing CF
$211,262,000
Financing CF
$371,730,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.64
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,352,379,000
Inventory
—
Receivables
—
ST Investments
$29,833,000
EBIT TTM
$-567,443,000
Pretax Income TTM
$-585,606,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -745,378,000 | -738,822,000 | 451,447,000 | 399,375,000 | 52,072,000 | -609,438,000 |
| Dec 2024 | 0 | -885,111,000 | -846,422,000 | 615,107,000 | 191,671,000 | 423,436,000 | -582,453,000 |
| Dec 2023 | 0 | -436,051,000 | -408,168,000 | 513,212,000 | 85,237,000 | 427,975,000 | -331,725,000 |
| Dec 2022 | 0 | -567,932,000 | -570,279,000 | 661,783,000 | 123,012,000 | 538,771,000 | -297,689,000 |
TTM Snapshot
Revenues TTM
$663,422,000
NetIncome TTM
$-586,841,000
OpCashFlow TTM
—
Assets (Latest)
$370,739,000
Forward EPS
$-1.79
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $12.90 · call volume: 3,086 · put volume: 176
Expected Move to 2026-12-18:
±$2.84
(22.02%) —
implied range
$10.06 –
$15.74
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMNM | Immunome Inc. | $2.03B | $17.18 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.94B | $33.01 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.06B | $15.40 | — |
| TRVI | Trevi Therapeutics, Inc. | $1.93B | $13.51 | — |
| SEPN | Septerna, Inc. | $1.90B | $40.02 | — |
News headlines (Yahoo Finance, 1h cache)
Could Graves Data Alter The Investment Case For Biohaven (BHVN)?
2026-11-14 01:12 · Yahoo
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
2026-11-05 12:30 · Yahoo
Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?
2026-10-30 15:10 · Yahoo
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
2026-10-29 20:02 · Yahoo
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade
2026-10-29 12:55 · Yahoo
JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight
2026-10-26 14:31 · Yahoo
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
2026-10-26 11:30 · Yahoo
Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says
2026-10-23 15:56 · Yahoo
Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance
2026-10-23 11:18 · Yahoo
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade
2026-10-23 02:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.